Company intelligence / Profile preview

Clearall AIT

Maryland, United Statessoflo.hhhexpo.com ↗

Ownership: Private
Development stage: Commercial

Overview

Clearall AIT offers a proprietary allergy testing and personalized treatment program using its AllergyScope device for precise diagnosis. Treatments include sublingual immunotherapy (SLIT) serums mailed to patients for at-home use and traditional allergy shots administered in-office. All treatments are designed by board-certified allergists based on individual patient profiles.

Therapeutic areas: Immunology
Modalities: Non-pharmacological therapySmall molecule (for sublingual immunotherapy serums)Biologic (for allergen extracts used in immunotherapy)
Industry: Biotech

Drug pipeline

2 assets

SLIT allergy immunotherapy

Commercial

Indications: Airborne allergies

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Clearall AIT.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clearall AIT.

Explore the full profile